GSC Biological and Pharmaceutical Sciences
eISSN: 2581-3250 CODEN (USA): GBPSC2
Cross Ref DOI: 10.30574/gscbps
Journal homepage: https://gsconlinepress.com/journals/gscbps/

(REVIEW ARTICLE)

Check for updates

Stability and bioequivalence challenges in generic drug formulation: A regulatory perspective

Maria Elise DuPont *

Senior Research in Pharmacogenomics, Harvard Medical School, Boston, USA.

GSC Biological and Pharmaceutical Sciences, 2025, 31(02), 166–178

Publication history: Received on 04 April 2025; revised on 27 May 2025; accepted on 29 May 2025

Article DOI: https://doi.org/10.30574/gscbps.2025.31.2.0189

Abstract

The testing of generic remedies is of great importance for welcoming affordable health care and the brand names. However, attaining the stability of a product and proving bioequivalence (BE) to reference medicines constitute a couple of the major formulation challenges toward the safety, efficacy, and quality assurance of generics. This paper takes a regulatory perspective to discuss these challenges comprehensively, thereby laying out the science, technology, and compliance principles facing generic drug developers. Stability is challenged by interactivity among APIs, excipients, and environmental conditions, with robust formulation and stability-indicating testing strategies envisaged for all possibilities. Bioequivalence studies also constitute one of the major hurdles for regulatory approval, thereby posing further design-specific challenges, such as variable absorption and differing effects of formulations, especially with modified-release formulations or when it comes to drugs with a narrow therapeutic index. Although regulatory expectations on stability data and BE demonstration as enforced by the FDA, EMA, and WHO are rigorous, in practice the differences in requirements between jurisdictions can impede submissions on an international level. Many avenues of emerging concern, focusing on the subjects of complex generics, the biowaiver, and regulatory harmony, are considered within the scope of the article.

Keywords: Bio Equi valance (BE); Federal Drug Administration (FDA); Prequalification of Medicines Programme (PQP); Abbreviated New Drug Application (ANDA); CHMP (Committee For Medicinal Products For Human Use); Chas (Critical Quality Attributes); Stability Testing

1. Introduction

The purpose of generic drug manufacturing processes is that they produce drugs in each and every respect similar to the innovator (brand) drugs in terms of dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. The most important criterion for attaining such equivalence is bioequivalence, which is the assurance that the rate and extent of absorption of the generic product in the body will not be significantly different from that of the original drug with the same dosage (Chen et al., 2001; Yacobi et al., 2014). Bioequivalence is the cornerstone of generic drug approval to ensure that they are therapeutically equivalent to their Branded counterparts (Meredith, 2003; Kanfer & Shargel, 2007). With this value as the basis for marketing approval, generics ensure prestige to the high standards of safety and efficacy towards the prevention of rising costs of health treatment in low- and middle-income countries, so Hasam et al. (2021) stress its importance worldwide. With less development costs, generics provide a saving to the health provider and the consumer, allowing for better adherence to therapies (Bate et al., 2016; Welage et al., 2001). As acceptance of generics continues to grow, the supply chain for pharmaceutical manufacturers has also become strengthened, and reduced their dependence on brand manufacturers (Bhushan & Martens, 2024). Rigorous approval processes have been laid out for generics, particularly complex generics, by

* Corresponding author: Maria Elise DuPont

regulators such as the FDA and EMA, while other efforts for international harmonization seek to simplify approval (Patil et al., 2024; Mühlebach, 2018; Mirando et al., 2019).

1.1. Importance of Bioequivalence and Stability

Bioequivalence and stability properties are key parameters for generic drug development and regulatory approval to assure therapeutic equivalence to their brand product counterpart. Bioequivalence ensures that the generic product delivers the same active substance at the same rate and extent as that of the innovator drug in preserving clinical efficacy and safety (Chen et al., 2001; Tamboli et al., 2010; Meredith, 2003). Regulatory agencies like the FDA and EMA have concentrated on bioequivalence testing, especially for complex generics and non-traditional dosage forms-such as topical, inhalation, and nanomedicines-adjudged to pose unique scientific and methodological concerns (Bate et al., 2016; Yacobi et al., 2014; Hussaarts et al., 2017; Mühlebach, 2018). Stability testing also ensures that the drug product maintains its identity, strength, quality, and purity throughout the shelf life, which are essential for assuring consumer safety and product efficacy (Hasan et al., 2021; Bhushan & Martens, 2024). As the regulatory framework for the assessment of bioequivalence and stability addresses complex and semi-solid products, these might entail advanced in vitro and in vivo models (Patil et al., 2024; Ilić et al., 2021; Miranda et al., 2022). Another important development is that regulatory expectations have started to include developments in analytical and statistical techniques employed in assessing variability with regard to narrow therapeutic index drugs or therapeutic equivalence.



Figure 1 Importance of Bioequivalence

Source: Bioequivalence Studies - FasterCapital. (n.d.). FasterCapital.

https://fastercapital.com/keyword/bioequivalence-studies.html

1.2. Scope and objectives

Now the focus is on regulatory background matters regarding bioequivalence and stability of generic drugs. Emerging standards and complexities confronting pharmaceutical manufacturers follow. Increasingly, regulatory authorities have demanded far higher quality data in demonstrating therapeutic equivalence and long-term stability of products, meaning the manufacturer has to present evidence from multiple domains-in vitro, in vivo, and statistical-evidence are especially relevant when dealing with relatively complex dosage forms such as injections, inhalers, and topical formulations (Patil et al., 2024; Yacobi et al., 2014; Lee et al., 2015). Scientific, technical, and administrative constraints randomizing against the demonstration of bioequivalence impose a burden onto the manufacturers such as drug absorption variation, absence of adequate testing methods, and contradicting world consensus regulatory expectations (Hussaarts et al., 2017; Meredith, 2003; Bate et al., 2016). The previously mentioned aims could also highlight challenges

to strategy formulation for drugs, product development timelines, and accessibility into markets while focusing on how stability testing ensures safety, efficacy, and compliance throughout the product lifecycle (Hasan et al., 2021; Bhushan & Martens, 2024).

2. Regulatory Framework for Generic Drug Approval

2.1. Overview of Key Regulatory Bodies

2.1.1. US FDA (Food and Drug Administration):

Approval of generic drugs involves the process laid down through the Abbreviated New Drug Application (ANDA), which is administered by the Office of Generic Drugs that requires evidence of bioequivalence to the reference listed drug, ensuring that the generic will match the brand in safety, efficacy, and quality in manufacturing (Chen et al., 2001; Welage et al., 2001). Contrary to the very lengthy and expensive process that new drugs undergo, the ANDA does not mandate complete clinical trials; therefore, generic drug development and approval become very cost-effective. A quick pathway for generics often results in prompt market entry, competitive pricing, an overall decreased cost of drugs, and increased patient access to affordable medications, without compromising therapeutic standards. Likewise, the review procedure in the ANDA framework ensures thorough scrutiny of the drug's chemistry, manufacturing controls, labeling, and stability data to maintain quality (Patel et al., 2024). Following the approval of ANDAs, the generics are subjected to constant regulatory oversight through routine inspections, reports of adverse events, and periodic updating to maintain compliance with current standards. These regulatory mechanisms jointly fortify one of the strongest regulatory systems that protect public health while promoting a sustainable market and innovation in generic drug development.

2.1.2. EMA (European Medicines Agency)

Once a generic drug is approved in the EU, it is under the centralized procedure combined with the procedure for decentralized approval with simultaneous evaluation by CHMP (Committee for Medicinal Products for Human Use). A generic must establish that the therapeutic equivalent of the reference product is present, as well as fulfill the standards of quality and good manufacturing practices. Hence, because of this harmonization in the EU member states, safety, efficacy, and quality of generics are guaranteed in the EU and hence these afford accessibility of medicines at low prices while upholding very high public health standards for the region (Patil et al, 2024: Hussaarts et al, 2017). The reason behind the central procedure is to have a market authorization valid in all member states of the EU, thereby ensuring access to the market and uniformity of the regulatory expectations. The decentralized procedure, on the other hand, grants concurrent approvals in different member states when the application aspect is seen considering that the product is a generic medicine intended for the market preferred in a certain national environment. Both regulatory pathways gobble up a full evaluation for every pharmaceutical document, including bioequivalence studies, methods of manufacturing, and stability testing. In addition, the EU regulatory framework supports provisions for post-marketing and pharmacovigilance for continued use of medicines.

2.1.3. WHO Prequalification Programme:

In this respect, the WHO's guiding principles and evaluation of generic medical products in developing countries somehow focus on assuring their quality, safety, efficacy, and stability for worldwide health requirements. The WHO evaluates generic products against international standards through the Prequalification of Medicines Programme (PQP), which not only builds confidence in their use but also helps procurement by global health agencies. It is one model for the NRAs without sufficient technical capability and other resources to diligently evaluate sufficiently on their own. Providing technical assistance, common assessment procedures, and capacity building, WHO seeks to enable NRAs to build their own regulatory systems. WHO's interventions further foster universal access to essential generic medicines, particularly in the areas of infectious diseases, maternal and child health, and chronic diseases. Those interventions will not only reduce health inequities but will also position sustainable pharmaceutical markets in a resource-poor setting (Hasan et al., 2021; Bate et al., 2016).

2.1.4. Other National Regulatory Agencies:

Countries such as India, Brazil, and China have established robust regulatory mechanisms for the approval and regulation of generic drugs, most often in synch with the WHO and ICH guidelines. These systems, by providing a national framework to meet specific healthcare needs, also serve to aid in the convergence of regulations globally. By following standardized, international norms for testing their medicines on quality, safety, and efficacy, these countries provide more credibility to their generic drug industries and assist in exporting cheap medicines to other territories.

Moreover, global alignment will support these countries in seamlessly entering the international market, while also helping to minimize delays in the evaluation of drugs so that the access to essential generics is fast-tracked at worldwide levels. These systems are indispensable for shaping regional pharmaceutical strategies, backing innovation, and ensuring that regulatory decisions reflect global best practices and local public health needs (Lee et al., 2015, Miranda et al., 2022).

2.2. Criteria for Generic Drug Approval

2.2.1. Pharmaceutical Equivalence

In the case of generic drugs, pharmaceutical equivalence is one of the foremost requirements for approval, whereby the generic product is bound to contain the same active ingredient(s), dosage form, route of administration, and strength as the reference listed drug. While the excipients (inactive ingredients) used in the formulation can differ between generic products and name-brand ones, this should not affect the safety, efficacy, or performance of the prescribed drug. Regulatory authorities assess for pharmaceutical equivalence whereby the generic product is determined to liberate the drug at a rate and extent that assures achieving the desired therapeutic effect in the patient. This principle is a unfailing basis for generic drug development, supporting confidence in the products' interchangeability and clinical effectiveness (Tamboli et al., 2010; Meredith, 2003).

2.2.2. Bioequivalence Requirements:

Bioequivalence, or BE, is one of the most important qualitative criteria in the process of approval of a generic drug. The generic drug should demonstrate that the rate and extent of absorption of an active moiety in a generic drug, and a reference listed drug are not significantly different. Such proof is established mostly through pharmacokinetic studies, which measure the parameters such as maximum concentration (Cmax), area under the concentration-time curve (AUC), and time to reach maximum concentration (Tmax). These represent quantitative measures of how the drug becomes distributed and eliminated in the body and confirm that the generic performs similarly as the brand-name product in vivo. Most of the BE studies will be compulsory; however, in some exceptional cases, similar waivers can be granted, for example for BCS Class I drugs, which are characterized by high solubility and high permeability, but which should also fulfill the established criteria for biowaiver. Such thresholds are that the 90% confidence intervals for the ratio of generic to reference product for Cmax and AUC fall within an accepted range of 80--125%, a threshold that assures therapeutic equivalence but with no sort of clinically meaningful difference in performance (Chen et al., 2001; Bate et al., 2016; Kanfer & Shargel, 2007).

2.2.3. Stability Data for Shelf-Life Determination

Stability studies in generic drug development processes essentially involve testing how well a drug product will retain its identity, strength, quality, and purity throughout its assigned shelf life according to International Council for Harmonization (ICH) guidelines for stability testing. Accelerated testing, exposing the product to stress conditions of higher temperature and humidity to simulate long-term storage, is conducted along with long-term tests at the recommended storage conditions. In their totality, the results substantiate the claimed shelf-life and storage conditions on the label so that the product remains effective and safe until the date of expiration. In addition, stability testing will explore the suitability of the packaging materials, ensuring that these materials can fully protect the product under the considered conditions throughout distribution and use. These evaluations are valuable in substantiating the therapeutic integrity of the generic drugs over time, thereby instilling patient and regulatory assurance from the good standing list of reliability (Hasan et al., 2021; Ranjan, 2025).

2.3. ICH Guidelines and Regulatory Harmonization

2.3.1. Stability Testing and Quality by Design and Risk Management

The ICH Q1 series (Q1A–Q1F) provides extensive guidance on the stability testing of new drug substances and products. ICH Q1A(R2) describes the fundamental approaches to stability testing such as testing conditions (temperature and humidity), time points, and packaging considerations. These guidelines guide the assignment of the shelf life, storage conditions, and retest period for the drug by employing long-term and accelerated storage conditions that the drug product is expected to tolerate. The criticality of the stability study in the regulatory filings lays in establishing the maintenance of drug quality, safety, and efficacy throughout the drug's proposed lifecycle. Stability data for the drug product that are generated as per ICH Q1A(R2) inform regulatory agencies that the product has satisfactory maintaining qualities under the proposed storage conditions pertinent to asking for market support and providing patient safety. Moreover, the ICH Q8–Q10 guidelines have been framed with the aim of building in product quality from the outset. This is considered as a byword principle for pharmaceutical development. ICH Q8 (Pharmaceutical Development) sets

key standards for a systematic, science-based approach in the formulation and manufacturing process, ensuring that only high-quality substances proceed through the channel to land up as high-quality products. The ICH Q9 (Quality Risk Management) process brought in, as risk analysis tools, such as Failure Modes and Effects Analysis (FMEA) and Hazard Analysis and Critical Control Points (HACCP) to prevent risks, which are capable of causing harm to product or consumer safety.

2.3.2. Differences and Convergences Among Global Regulations

Broadly speaking, the regulatory agencies in the United States (FDA), Europe (EMA), and Japan (PMDA) follow the ICH standards for the approval and regulation of medicines. However, they might differ in having some additional requirements of data or may have different perspectives in certain areas, such as risk assessments, formats of dossier, or duration of stability studies. The regulatory agencies try to follow the ICH guidelines in ensuring the safety, efficacy, and quality of pharmaceutical products, while definitely having slight variations in their regulatory processes to meet the needs of the country or region. Some emerging markets like India, China, and Brazil have increasingly begun to follow the ICH standards, signifying a move towards global harmonization of regulations. However, localized differences still exist, especially in areas such as bioequivalence data and post-approval change requirements and expectations related to inspections, since such countries are still evolving their regulatory frameworks in relation to specific healthcare environments and available resources (Lee et al., 2015; Hasan et al., 2021). In addition, the principles of ICH have been adopted to a great extent within the Prequalification Program of WHO, especially with regard to essential medicines for global health initiatives. In this way, the WHO is able to ensure that medicines produced according to its recommendations will be internationally accepted as high quality and safe, thus improving access to vital treatments through public health programs accessed by low- and middle-income countries.

3. Stability Challenges in Generic Drug Development

3.1. Stability Testing



Figure 2 Stability Testing

Source: Introduction to stability Testing - FasterCapital. (n.d.). FasterCapital.

https://fastercapital.com/topics/introduction-to-stability-testing.html

The main purpose of accelerated tests is to reduce significantly the time taken by long-term stability studies due to elevated stresses on the product (such as 40°C ± 2°C/75% RH ± 5%) so that degradation trends can be evaluated to support shelf-life projection. Long-term studies assess stability under realistic storage conditions (such as 25°C ± 2°C/60% RH ± 5%) which are used for regulatory filing purposes and post-approval monitoring to assess the actual

shelf-life of the product. Intermediate studies are performed under conditions standing between acceleration and long-term conditions so that one can ascertain whether any product fails under guardband conditions. Stability-indicating methods like HPLC means basically A&M-analytical method to signify any variation in identity, potency, purity, and safety of drug substances or products. These methods separate the API from its degradation products; through this separation, signs of possible stability issues are available, thus proving that the product remained within regulatory breaches during its stipulated shelf life.

3.2. Factors Affecting Stability

API degradation pathways may be activated by many chemical processes, viz., hydrolysis, oxidation, photolysis, or isomerization, etc. Hydrolysis is, rather, the main degradation pathway for ester-containing APIs, especially under humid conditions. Furthermore, excipients could interact with the APIs negatively to affect drug stability. For example, lactose causes Maillard reactions when reacting with amine-containing APIs. Other factors affecting drug stability include temperature, humidity, and light exposure. For instance, high humidity favours hydrolysis, while UV light can act as an agent for photodegradation of the drug and further jeopardize its stability and efficacy. Such factors, thus, should be carefully considered in developing and storing pharmaceutical products to protect their safety and efficacy.

3.3. Formulation and Packaging Issues

Compatibility of the drug with other excipients is an important subject in drug development which has to be done in preformulation to prove that excipients do not catalyze the degradation of the active pharmaceutical ingredient or reduce its bioavailability. It would help find out what portions of incompatibilities between the API and excipients may actually jeopardize the drug's efficacy or stability in addition to that, important in drug stability is packaging. The packaging protects drugs from moisture, oxygen, and light, for instance; blister packs with aluminum foil are some of the compared highly effective barrier systems in preventing moisture ingress and maintaining drug stability. Clearly, on the other side, inadequate or poor packaging will eventually lead to a loss of shelf-life or product failure during distribution, which underlines the cardinality in choosing proper packaging materials for product integrity and quality in the pharmaceutical lifecycle.

3.4. Case Examples of Stability Failures

Hence stability assumes critical importance in all approval processes. Another black-eyed incident has come from a recalled generic antihypertensive product that formed nitrosamine impurities during storage, faced with high humidity. Unfavorable stability control against incidence root cause analyses mostly flagged error generators, such as poor excipient compatibility, poor packaging choice, or noncompliance with validated storage conditions. Near incident examples underscore that formulation development and stress testing must go hand in hand to ensure the drug's stability in all environmental conditions. From incidents such as this, early assessment of stability risks, complete impurity profiling, and the establishment of predictive models to project long-term trends of degradation inclinations will be key to product quality, safety, and regulation.

4. Bioequivalence (BE) Challenges

4.1. Definition and Significance

4.1.1. Role of BE in Ensuring Therapeutic Consistency

Bioequivalence (BE) is a very important aspect for demonstrating therapeutic consistency, not least for gaining approval of generic medicines and acceptance of use for these products. According to BE, the generic drug is compared with its reference listed drug (RLD) in order to establish equivalence in terms of relevant concentrations of the active pharmaceutical ingredient (API) within the bloodstream over time. The extent of this phenomenon guarantees that the generic is therapeutically effective and safe for the patient. BE studies become decisive in conditions where even minor differences in absorption may affect clinical outcome, as occurs in conditions of treatment such as epilepsy, cardiovascular diseases, or organ transplantation. When BE is proved, regulatory agencies will not hesitate to endorse generic substitution, thereby promoting cost-effective healthcare and safety for patients.

4.1.2. Types of BE Studies

The classification of biocompatibility studies is derived on the basis of methodology employed to show equivalence between a generic drug and its parent compound. In vivo BE studies being the most common and involve the administration of a test and reference product to healthy subjects or patients to study plasma drug concentrations at different time points. From this, pharmacokinetic parameters Cmax, Tmax, and AUC can be generated, which are further

compared to within regulatory limits (ordinarily 80-125% into the 90% confidence interval). In vitro BE studies, however, test the dissolution profile of the drug in a controlled laboratory environment. These studies are applicable mostly for solid oral dosage forms and can be used as initial tools or as supporting evidence for BS. BCS-based biowaivers apply to drugs sitting as Class I in the Biopharmaceutics Classification System with high solubility and high permeability. In vivo studies can be waived for such drugs if the formulation shows rapid dissolution and meets other regulatory standards, thus accelerating the process of generic drug approvals for already extensively characterized molecules. The diversity of types of BE studies is pivotal to assuring therapeutic equivalence for generics without the need of duplicated clinical trials.



Figure 3 Types of Bioequivalence studies

Source: Gavitt, M. (2017, October 11). *Principles of Interchangeability Testing Alfredo García – Arieta, PhD*. Ppt Video Online Download. https://slideplayer.com/slide/3256875/

4.2. Study Design Considerations

4.2.1. Crossover VS Parallel Design

In East Africa, the crossover design is most commonly used for bioequivalence study design. In each study period, the subject is given the test product, and on one or two alternate study days, the reference product is given, with a washout phase in between the administrations to allow elimination of possible residual drug effects. Thus, this design minimizes the intersubject variability by having each subject serve as his/her own control and enhances the precision of pharmacokinetic comparisons. The parallel design, on the other hand, is one in which different groups of subjects are assigned to receive either the test product or the reference product, and comparisons are made across the groups. This design is used particularly when a crossover design is not feasible, for instance, in case of drugs that are with long half-life elimination requiring a long wash-out period. Both designs form important tools to ensure that BE studies generate data that are robust and reliable in support of the approval of generic medicines.

4.2.2. Fasting vs Fed State Conditions:

Bioequivalence study conditions therefore feature 'fasting' and 'fed' conditions in preclinical trial studies. Giving the test drug in the first instance after an overnight fasting period will tend to reduce variability introduced by extrinsic factors and focus on the intrinsic absorption characteristics of the drug, as food has an effect on gastrointestinal tract transit time and activity of enzymes. In place of 'fed conditions' these appear after the administration of a standardized high-fat, high-calorie meal, and are primarily relevant to drugs with food-dependent absorption, as they are mimesis of

the true clinical scenario, with patients feeding along with medication. Regulatory bodies may want both conditions proving consistency in effective therapeutic performance in real conditions of biased usage.

4.2.3. Statistical Analysis and Acceptance Criteria:

Statistical analysis is fundamental in bioequivalence (BE) studies, which verify that both generic and reference products produce comparable pharmacokinetic results. Within bioequivalence, these greater parameters can be checked statistically by analyzing a variance (ANOVA) or a t-test for Cmax (the maximum concentration value) and AUC (the value under the curve), as they represent the rate and extent of absorption. All such results are usually expressed as the ratio between the two generic and reference products, which is declared by the regulatory perspective to be within the approval criteria of the 90% confidence interval of the ratios under the range of 80% to 125%. This statistical range indicates that no clinically significant difference exists among the products, thus assuring them equivalently therapeutic in nature.

4.3. Formulation-Related Issues

Differences in excipients may not have any pharmacological activity, but they can considerably influence drug absorption by means of dissolution rates and availability variations. Differences in binders, fillers, or lubricants between generic and reference formulations may manifest with measurable differences in plasma levels of the drug, an effect that complicates bioequivalence (BE) assessment. This is further complicated by MR products since their extended-release mechanisms generally require the generic formulation of the MR product to strictly follow that of the reference product, which may be quite a challenge without some in vitro special tests. As for IR products-these are good to go as they release the API rapidly, hence, fewer barriers to BE, although dissolution and absorption are still expected to finish under very tight regulations. For NTI drugs-those wherein dose administered is close to the toxic threshold-even slight deviations in any manner of drug exposure can pose real threats for patients. Thus, BE studies for NTI drugs tend to use more stringent analytical conditions, and regulatory agencies impose stricter criteria for acceptance.

4.4. Biowaivers and BCS Classification

Most often, biowaivers, which relate to the waiver of in vivo bioequivalence (BE) studies, are given for pharmaceutical classification viaducts.



Figure 4 Bio Pharmaceutics Classification

Source: Shinde, V. (2025, February 14). *Biopharmaceutics classification system and eligibility for bio waivers*. Veeprho. https://veeprho.com/bio-pharmaceutics-classification-of-drug-substance-and-eligibility-for-bio-waivers/

These are often BCS class I-high solubility and high permeability drugs, having immediate - release formulation with no known issues vis-a-vis bioavailability. In such a case, strong in vitro dissolution reports indicating that the release profile of the generic product is comparable to that of the reference one would suffice for approval under the regulation. However, there are various limitations and hot discussions about biowaivers. They are, generally, not granted with drugs of lesser permeability, e.g., BCS class III, encountered changes in excipients and complex formulations. Even qualifying medicines should undergo in vivo studies if they raise concern with regards to therapeutic equivalence. Bioequivalence is derived from studies held with in vivo conditions where an early intervention requirement for an infant pre-marketing would be waived.Tagging of biowaivers waives in vivo bioequivalence studies under certain conditions mainly for BCS Class I drugs, those possessing high solubility and high permeability, especially if it is an immediate-release formulation without any known issue affecting bioavailability. In such cases, solid in vitro dissolution data showing that the release profile of the generic product is comparable to that of the reference product suffices for regulatory approval. Nevertheless, these biowaivers have certain limits and still spark controversies. Most often, they are denied for drugs of lower permeability (such as BCS class III) and may require even some qualified drugs to undergo an in vivo study where the excipients differ or the formulation becomes complex enough to raise a concern about the therapeutical equivalence.

4.5. Common BE Failures

The reason ascribed to regulatory non-approval of generic drugs is often bioequivalence failures. Bioequivalence affects mainly these drugs with complex formulations or that fall under narrow therapeutic index (NTI) drugs. One such example is an anti-epileptic, phenytoin, whose generic product is not approved on the grounds of BE due to variability in the absorption attributed to formulation. This incident had a very striking parallel in the case of an extended-release generic that failed BE testing on the grounds of changed release, leading to very different plasma levels of the drug compared with those achieved by the reference. Formulation or manufacturing process changes can also alter bioequivalence results. Excipients' switching or changing a production step, for example, as with granulation, may lead to changed dissolution rates and bioavailability. One process changes the dissolution slowed down and this was used by the regulatory agency to reject on the passport of nonequivalence.

5. Regulatory Challenges and Industry Compliance:

5.1. Consistency Across Regulatory Agencies

Discrepancies in the data requirements and evaluation criteria of regulatory agencies like the US FDA and EMA, as well as national authorities, present a major challenge to generic drug approval. Most often, the FDA would require pharmacokinetic equivalence and permit biowaiver on some BCS Class I drugs based on in vitro data, whereas also requiring in vivo studies in EMA alongside stability data or even post-marketing surveillance. This creates inconsistency with regulatory expectations. These fluctuations would create complexity when trying to implement one single regulatory strategy, especially with pharmaceutical companies that try to submit to many countries. The submissions will have to worry about different standards for each individual regulatory body such as specific bioequivalence testing protocol differences, excipient composition tolerances, and data package requirements. In effect, the approval process can stretch longer and become more costly, usually with extra studies necessitated to meet the regulations of a specific country.

5.2. CMC (Chemistry, Manufacturing, and Controls) Considerations

CQAs (Critical Quality Attributes) are defined as characteristics the drug product must maintain within certain predefined limits to ensure safety, efficacy, and quality. These include potency, dissolution rate, particle size, and impurity levels, and each has effects on therapeutic performance and stability of the product. The CQAs are analytically followed throughout the life cycle of a drug product, starting from development and extending to any post-approval changes.

Validation of the process and scale-up remains a key in verifying that product characteristics are unchanged during technology transfer from development to commercial manufacture. Small changes in time, temperature, or conditions during scale-up may alter the dissolution pattern or impurity profile of the active substance and may have a direct impact on bioequivalence and stability. As a result, these will necessitate the regulatory agencies to ensure that additional validation studies are conducted to confirm that each respective increased scale can carry out maintaining the same established quality and performance of the product as seen in the clinical batches by ensuring that therapeutic equivalence is maintained in the final marketed form.

6. Emerging Issues and Future Directions

6.1. Complex Generics and Biosimilars

BE and Stability Demonstration: Extra Complexities: There is the implication in the method establishing BE and stability for complex generics and biosimilars due to their molecular structure and mode of action. A simple generic drug under the category of traditional generics is a copy of the branded drug; complex generics may have new dosage forms, complex API, or even biologics difficult to replicate. More difficult than demonstrating BE for biosimilars are owed to the fact that the reference products themselves are biologics that vary inherently. Such products undergo rigorous clinical studies, including pharmacokinetic and pharmacodynamic comparisons and tests to establish their stability under various conditions. These formulations are indeed complex and becoming a bit more challenging in terms of immunogenicity to maintain consistent therapeutic outcomes.



Figure 5 Biosimilar VS Generic Drugs

Source: Collazo, K. (2024, May 1). *Biosimilar vs Generic Drugs: Key Differences in Healthcare*. Medical Packaging Inc., LLC. https://medpak.com/biosimilar-vs-generic-drugs/

6.2. Novel Drug Delivery Systems

Regulatory Lapses in Evaluating Novel Generics: Novel drug delivery systems, such as nanotechnology formulations, liposomes, and sustained-release systems, are increasingly being manufactured. These systems may have a different release profile, altered pharmacokinetics, and a new mechanism of drug absorption or action. But present standard regulatory approaches usually do not fully meet the specific challenges posed by these new delivery systems. In that, the established routes of bioequivalence assessment, largely set alongside their application to simple oral dosage forms, may simply not hold for those meant for complex or modified-release or targeted delivery systems. So, regulatory agencies are actually in the process of setting new standards for assessing the efficacy of these systems, which frequently imposes requirements for additional studies to be carried out, data regarding long-term stability, and special testing of the interaction between the drug, excipients, and delivery system.

6.3. Regulatory Science and Innovations

Modern bioequivalence occurs concurrently with the pharmaceutical production undergoing major alterations via the newer technologies of simulation and modeling and continuous manufacturing.PBPK models offer solutions to very specific drug development problems, widening the scope of possibilities before the different actors in the field. It mechanistically predicts and describes a formulation's processes of absorption-distribution-metabolism-excretion of drugs. Aiding regulators and manufacturers in foreseeing possible bioequivalence outcomes prior to actually weighing in an in vivo study is beneficial so as to reduce dependence on expensive and time-consuming clinical trials. The very utmost extent of change that can be conducted using such simulations via changes in formulation or manufacturing shall be conducted through PBPK modeling so that the time for development can be immensely reduced while still ensuring that the therapeutic equivalency actually remains very close to that of the reference product. Continuous manufacturing would be more appropriate to replace batch machining traditional manufacturing to yield utmost control, consistency, and scale-up potential. In contrast to every other parameter, stability was monitored real-time with sensors and analytical tools detecting deviation from critical quality parameters.

6.4. Global Harmonization Efforts

The global bodies. like ICH and WHO are working towards improving the drug registration framework by harmonizing regulatory requirements. In this regard, ICH guidelines from other quality aspects, such as stability (Q1) and pharmaceutical quality (Q8-Q10), promulgate that data generated in one region should be accepted by the other to avoid duplication. Meanwhile, WHO-prequalification significantly benefits generic medicines in ensuring global standards of quality, safety, and efficacy, especially in resource-limited countries. These processes take off much regulatory burden from pharmaceutical companies filing in multiple countries.

The digital technologies and AI have further entered into the domain of regulatory sciences. So, AI tools analyze data from clinical trials, manufacturing, and stability studies for insights, predicting outcomes, and potential regulatory risks. Potential bioequivalence issues are predicted ahead of time through simulations of formulation/process changes using these technologies, thereby possibly reducing binding clinical studies. Simultaneously, real-time data analytics allow regulators to move towards a proactive approach to compliance.

7. Conclusion

Summary of Key Challenges

While stability and bioequivalence remain challenges with generic drugs, a product is required to keep its potency and safety with efficacy throughout its shelf-life. The interaction of excipients and environmental factors such as temperature, humidity, and light coupled with the formulation parameters may render the potentials to initiate degradation mechanism-say, oxidation and hydrolysis of the drug. Stability thereby becomes an issue not just with the quality of the product but with the bioequivalence as well. Measuring HE has become a big challenge for innovative formulations compared to technically difficult generics and biosimilars, as these always pose a challenge to the usual methods of pharmacokinetic comparison. Regional variations in regulatory requirements compound the situation, thereby making it even more challenging for manufacturers to obtain global approval and meet all regulatory standards.

Recommendations

The challenges in stability and BE during generic development ought to be preempted in the beginning, thereby requiring an essentially strategic approach. Strategizing formulation planning would thus involve selecting excipients in terms of their stability profile, running compatibility programs with the API, and taking into consideration any environmental parameters that may influence product integrity. Avoiding BE concerns should make the development phase more amenable insofar as complex formulations or modified-release products are involved. Identifying and controlling critical parameters leading to stability and BE failures at early development stages is another advantage of building in QbD. Along with that, early and ongoing engagement with the regulatory authorities allows for alignment to current expectations, clarification on the designs of studies, and acceptance of early feedback. Such upfront communication will not only enhance the efficiency of development and prevent regulatory holds but also significantly improve first-cycle approval chances for complex generics.

Future Outlook

With increased sophistication in pharmaceutical development, regulatory frameworks are anticipated to evolve to address the issues posed by the complexities of contemporary generics, biosimilars, and novel drug delivery systems. Future changes may well usher in greater recognition of in silico modeling, consideration of adaptive pathways as a legitimate approval option, continuous manufacturing, and real-time monitoring of stability, which would in turn accelerate the drug approval process. Emerging technologies such as artificial intelligence, machine learning, and digital analytics are set to bring radical changes in development and compliance. They shall allow for better prediction of stability and BE outcomes, optimization of manufacturing processes, and less dependency on large-scale clinical trials. Real-time monitoring coupled with AI-driven simulations heralds a new era in which drug development and regulatory submissions are more fluid, dynamic, and responsive.

References

[1] Patil, S., Kumar, S., Rao, D. M., & Rewatkar, K. (2024). Current Regulatory Framework and Challenges for the Approval of Complex Generics in the US and the EU. Current Indian Science, 2(1), E2210299X269535.

[2] Bate, R., Mathur, A., Lever, H. M., Thakur, D., Graedon, J., Cooperman, T., ... & Fox, E. R. (2016). Generics substitution, bioequivalence standards, and international oversight: complex issues facing the FDA. Trends in pharmacological sciences, 37(3), 184-191.

[3] Tamboli, A. M., Todkar, P., Zope, P., & Sayyad, F. J. (2010). An overview on bioequivalence: regulatory consideration for generic drug products. J Bioequiv Availab, 2(4), 086-92.

[4] Yashu, F., Saqib, M., Malhotra, S., Mehta, D., Jangid, J., & Dixit, S. (2021). Thread mitigation in cloud native application development. Webology, 18(6), 10160–10161. https://www.webology.org/abstract.php?id=5338s

[5] Hussaarts, L., Mühlebach, S., Shah, V. P., McNeil, S., Borchard, G., Flühmann, B., ... & de Vlieger, J. S. (2017). Equivalence of complex drug products: advances in and challenges for current regulatory frameworks. Annals of the New York Academy of Sciences, 1407(1), 39-49.

[6] Cherukuri, B. R. (2020). Microservices and containerization: Accelerating web development cycles.

[7] Jangid, J., & Malhotra, S. (2022). Optimizing software upgrades in optical transport networks: Challenges and best practices. Nanotechnology Perceptions, 18(2), 194–206. https://nano-ntp.com/index.php/nano/article/view/5169

[8] Chen, M. L., Shah, V., Patnaik, R., Adams, W., Hussain, A., Conner, D., ... & Williams, R. (2001). Bioavailability and bioequivalence: an FDA regulatory overview. Pharmaceutical research, 18, 1645-1650.

[9] Meredith, P. (2003). Bioequivalence and other unresolved issues in generic drug substitution. Clinical therapeutics, 25(11), 2875-2890.

[10] Ilić, T., Pantelić, I., & Savić, S. (2021). The implications of regulatory framework for topical semisolid drug products: From critical quality and performance attributes towards establishing bioequivalence. Pharmaceutics, 13(5), 710.

[11] Hasan, M. I., Shimu, S. A., Akther, A., Jahan, I., Hamiduzzaman, M., & Hasan, A. N. (2021). Development of generic drug products by pharmaceutical industries considering regulatory aspects: a review. Journal of Biosciences and Medicines, 9(10), 23-39.

[12] Mühlebach, S. (2018). Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?. Advanced drug delivery reviews, 131, 122-131.

[13] Martinez, M., Langston, C., Martin, T., & Conner, D. (2002). Challenges associated with the evaluation of veterinary product bioequivalence: an AAVPT perspective. Journal of veterinary pharmacology and therapeutics, 25(3), 201-220.

[14] Bhushan, R., & Martens, J. (2024). Generic pharmaceuticals, regulatory aspects, bioequivalence investigation, and perception. Expert Opinion on Drug Safety, 23(2), 177-186.

[15] Patel, N. A., & Patel, N. R. (2024). Analytical techniques for peptide-based drug development: Characterization, stability, and quality control. International Journal of Science and Research Archive, 12(1), 3140-3159.

[16] Karalis, V. D. (2016). From bioequivalence to biosimilarity: the rise of a novel regulatory framework. Drug research, 66(01), 1-6.

[17] Cherukuri, B. R. (2024). Containerization in cloud computing: comparing Docker and Kubernetes for scalable web applications.

[18] Welage, L. S., Kirking, D. M., Ascione, F. J., & Gaither, C. A. (2001). Understanding the scientific issues embedded in the generic drug approval process. Journal of the American Pharmaceutical Association (1996), 41(6), 856-867.

[19] Lee, S. L., Saluja, B., García-Arieta, A., Santos, G. M. L., Li, Y., Lu, S., ... & Lyapustina, S. (2015). Regulatory considerations for approval of generic inhalation drug products in the US, EU, Brazil, China, and India.

[20] Miranda, M., Veloso, C., Brown, M., Pais, A. A., Cardoso, C., & Vitorino, C. (2022). Topical bioequivalence: Experimental and regulatory considerations following formulation complexity. International Journal of Pharmaceutics, 620, 121705.

[21] Shah, V. P., & Crommelin, D. J. (2016). Regulatory issues and drug product approval for biopharmaceuticals. In Pharmaceutical Biotechnology (pp. 463-470). CRC Press.

[22] Mitra, A., & Wu, Y. (2012). Challenges and opportunities in achieving bioequivalence for fixed-dose combination products. The AAPS journal, 14, 646-655.

[23] Kanfer, I., & Shargel, L. (2007). Generic drug product development: bioequivalence issues. CRC Press.

[24] Cherukuri, B. R. Developing Intelligent Chatbots for Real-Time Customer Support in E-Commerce.

[25] Ranjan, R. (2025). Development of Complex Generics and Similar Biological Products: An Industrial Perspective of Reverse Engineering. AAPS PharmSciTech, 26(4), 95.

[26] Nation, R. L., & Sansom, L. N. (1994). Bioequivalence requirements for generic products. Pharmacology & therapeutics, 62(1-2), 41-55.

[27] Bioequivalence Studies - FasterCapital. (n.d.). FasterCapital. https://fastercapital.com/keyword/bioequivalence-studies.html

[28] Introduction to stability Testing - FasterCapital. (n.d.). FasterCapital. https://fastercapital.com/topics/introduction-to-stability-testing.html

[29] Gavitt, M. (2017, October 11). Principles of Interchangeability Testing Alfredo García – Arieta, PhD. Ppt Video Online Download. https://slideplayer.com/slide/3256875/

[30] Shinde, V. (2025, February 14). Biopharmaceutics classification system and eligibility for bio waivers. Veeprho. https://veeprho.com/bio-pharmaceutics-classification-of-drug-substance-and-eligibility-for-bio-waivers/

[31] Collazo, K. (2024, May 1). Biosimilar vs Generic Drugs: Key Differences in Healthcare. Medical Packaging Inc., LLC. https://medpak.com/biosimilar-vs-generic-drugs/